clinical trial · NCT07288567
A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Schizophrenia in Adolescents (EMERGENT TEEN)
Bristol-Myers Squibb·phase3·recruiting·n = 166
SchizophreniaKarXTKarXT Matching Placebo
brief summary
The purpose of this study is to evaluate the efficacy and safety of KarXT for treatment of Schizophrenia in adolescents.
started
Jan 29, 2026
primary completion
Dec 18, 2029
completion
Dec 18, 2029
last updated
Apr 7, 2026
official title
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Schizophrenia in Adolescents (13 to 17 Years of Age)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol